Contact Us Trius Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious, life-threatening... infections In The News July 08, 2013Trius to Present at the JMP Securities Healthcare Conference June 12, 2013Trius Therapeutics Announces Publication of Antibiotic Safety Study...

Therapeutics Trius Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious infections. The... Company's lead investigational drug, tedizolid phosphate, is a novel antibiotic in Phase 3 clinical development for the treatment of serious gram-positive infections, including...

June 12, 2013Trius Therapeutics... Previous Release | Next Release June 12, 2013 Trius Therapeutics Announces Publication of Antibiotic Safety Study in Antimicrobial Agents... and Chemotherapy Peer-Reviewed Results Suggest No Clinically Significant Interactions Between Trius' Experimental Antibiotic Tedizolid and a Commonly Used Class of Medications SAN DIEGO..., June 12, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery, development and commercialization of antibiotics...

effective antibiotic to patients with serious infections. We are making timely progress in preparing tedizolid for global approval by including both the FDA as well as the European... Trius to benefit from certain incentives for the development of new antibiotics, including priority review and eligibility for fast-track status. We received the designation for our... therapy (OPAT) market and the retail pharmacy market. Today, the hospital accounts for nearly 60% of antibiotic usage and the remainder is roughly divided between the OPAT market...

Media Event Innovation in Antibiotics; Medicine for the Next Wave of Bacterial Infections Listen to webcast Mar 23, 2011 1:30 PM PT Trius Therapeutics 2010 Fourth Quarter Earnings...